Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2023 / Articles / Jul / Bringing Knowledge Back to Earth
Discovery & Development Drug Discovery Trends & Forecasts Research News Business & Trends

Bringing Knowledge Back to Earth

A quick tour of just some of the developments in space-based medicine

By Rob Coker 07/28/2023 4 min read

Share

Cosmonaut and International Space Station (ISS) flight engineer Dmitri Petelin recently conducted the latest in a long, long string of experiments involving hair and saliva samples to learn more about the effects of microgravity on the human immune system. In 2022, fellow cosmonauts Denis Matveev and Sergey Korsakov performed similar experiments, as did British astronaut Tim Peake back in 2016. As far as I can see, such studies began in 1975. So what has been learned?

Microgravity is known to affect both the innate and adaptive parts of the immune system. In 2021, immuno-bioengineering researchers in New York and Abu Dhabi published a study on microgravity’s effect on cells in the innate immune system – the body’s first line of defense against a pathogen – and on neutrophils (the most abundant granulocyte in the immune system) specifically. Methods involved real microgravity, including during parabolic space flights, in drop towers, aboard the ISS, and through simulated microgravity using rotation under different conditions. The samples had to be as close to the center of rotation as possible to mitigate the effects of fluid dynamics. The study reported increases in circulating neutrophils in humans returning from (long-term) spaceflight (1), and concluded – somewhat vaguely – that further experiments and improved testing methods and equipment were required. So, what could an increase in neutrophils mean for our spacefaring successors?

In a 2004 study (2), researchers affiliated with NASA Johnson Space Center stated: “Exploration class human spaceflight missions will require astronauts with robust immune systems. Innate immunity will be an essential element for the healthcare maintenance of astronauts during these lengthy expeditions. By investigating neutrophil phagocytosis, oxidative burst, and degranulation of 25 astronauts after four space shuttle missions, and witnessing an 85 percent increase of neutrophils at landing compared to preflight levels [this study indicates] that neutrophil phagocytic and oxidative functions are affected by factors associated with space flight and this relationship may depend on mission duration.”

Warp speed back to 2023 and a study led by researchers at the Amity Centre of Excellence in Astrobiology, Amity University Mumbai, India, indicates that, due to observational changes in the gut microbiome, probiotics are key to maintaining the long-term health of astronauts (3). Physiological changes have been known to affect mental health and lead to genitourinary tract infections, reduced immunity and changes in immune response, cardiovascular issues, and the development of cancer. “Probiotics help tackle these health issues caused during spaceflight by inhibiting pathogen adherence, enhancing epithelial barrier function by reducing permeability, and producing an anti-inflammatory effect,” the study authors note. Similar to the conclusion of the 2021 study, the researchers also admit that more needs to be done to validate the theory.  

In the meantime, experiments with microgravity continue. For example, Israel-based SpacePharma, co-founded in 2012 by satellite scientist Yossi Yammin and inventor and gastroenterologist Martin Aebi, invites researchers to bring their science to its shoebox-sized laboratory in the search for solutions that will be effective in microgravity. Whilst onboard the ISS, and through the use of the microgravity lab, scientists such as Petelin cultivated human skin cells (keratinocytes and fibroblasts) in 2D or 3D culture systems to assess their ability to produce extracellular matrices. The aim? To better understand fundamental biological processes to support the development of new therapies, devices, and tools for wound healing, aging, and scarring. The scientists also worked on production of a phyto-nanoemulsion to boost therapeutic effect and increase the stability of the final product.

In March 2023, SpacePharma successfully launched its fourth generation microgravity lab onto the ISS via the SpaceX vehicle, returning it safely in April.

For those less likely to be selected for the next ISS mission (especially those with a Bachelor’s degree in any biomedical or clinical science), applications to study on an Executive Space Course, Medicines in Space* at the International Space University are being accepted. Attendants will be able to hear first-hand from the developers and users of the microgravity lab from SpacePharma. Other topics covered include the effects of microgravity on physiology, the needs and capabilities of current medical systems, and life science-based space careers.

The topic of medicines in space may not have exactly blasted off, but it does seem to be getting off the ground. All we can do is count down to the potential out-of-this-world results that this relatively young science may generate.

*November 12–16, 2023, €3,900/$4,200. Strictly limited to 50 participants

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. M ElGindi et al, “May the Force Be With You (Or Not): The Immune System Under Microgravity”, Cells (2021). PMID: 34440709
  2. I Kaur et al, “Changes in neutrophil functions in astronauts”, Brain Behav Immun (2004). PMID: 15265537
  3. R Jobby et al, “Prospective Use of Probiotics to Maintain Astronaut Health during Spaceflight”, Life (2023) 13 (3); 727. https://doi.org/10.3390/life13030727

About the Author(s)

Rob Coker

Following a Bachelor’s degree in English Literature and a Master’s in Creative Writing, I entered the world of publishing as a proofreader, working my way up to editor. The career so far has taken me to some amazing places, and I’m excited to see where I can go with Texere and The Medicine Maker.

More Articles by Rob Coker

False

Advertisement

Recommended

False

Related Content

Understanding the H5N1 Threat
Vaccines Drug Discovery
Understanding the H5N1 Threat

February 3, 2025

4 min read

With new cases of avian influenza appearing, what does this mean for global health and what are drug developers doing about it?

Battle of the Superbugs
Drug Discovery Technology and Equipment
Battle of the Superbugs

December 1, 2014

0 min read

Can phage endolysins revolutionize the way bacterial infections are treated – and prevent drug resistance?

Antibiotics: Going With the Flow
Drug Discovery Small Molecules
Antibiotics: Going With the Flow

April 2, 2025

2 min read

How fluid flow through the body can affect the ways in which antibiotics work.

Combatting the Side Effects of Treatments for Parkinson’s
Drug Discovery Small Molecules
Combatting the Side Effects of Treatments for Parkinson’s

April 7, 2025

4 min read

Celon Pharma CEO hopes their new compound could be a potential breakthrough for Parkinson’s patients.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.